Has Paul Simonelli, MD received payments from drug or device companies?

Yes. Drug and device makers reported $21,321 in general payments to Paul Simonelli, MD across 24 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paul Simonelli, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paul Simonelli, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paul Simonelli, MD

Pulmonary Disease · Danville, PANPI 1013918424

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $18,701 of the $21,321 with a category attached, or 87.7%. 6 manufacturers reported payments, led by Genentech USA, Inc. at 32.0% of the total. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,321in general payments, 2019–2025

Across 24 payments — averaging $888.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech USA, Inc.$7K
Gilead$7K
AstraZeneca$5K
Genentech, Inc.$3K
Merck$36
Pulmonx Corporation$20

$2,053,080in research payments, 2019–2025

Across 39 payments — averaging $52,643 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

GSK$1.7M
Regeneron$357K

What the payments were for

Consulting fees$18,70188%
Travel & lodging$1,8489%
Food & beverage$7363%
Education$360%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech USA, Inc.	8	$6,823
Gilead	9	$6,799
AstraZeneca	2	$4,760
Genentech, Inc.	2	$2,883
Merck	2	$36
Pulmonx Corporation	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Veklury$6,535

How this compares

$21,321 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$38,071

Medicare patients

570

Services billed

1,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Aralast NpAlpha-1-Proteinase Inhibitor	13	$143,284
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	64	$69,497
Dupixent PenDupilumab	13	$49,244
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	31	$26,907
Breo ElliptaFluticasone/Vilanterol	28	$17,490
Spiriva HandihalerTiotropium Bromide	14	$7,839
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate	20	$5,267
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	14	$2,805
Albuterol Sulfate HfaAlbuterol Sulfate	32	$2,782
Ventolin HfaAlbuterol Sulfate	11	$1,737
Montelukast Sodium	34	$1,439
Prednisone	44	$543
Azithromycin	20	$439
Duloxetine Hcl	12	$93

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Danville

Sandeep Bansaldu Bois$1.4M
Alan KanouffAltoona$809K
Gerard CrinerPhiladelphia$657K
Kenneth LanderUpland$647K
Richard FriedenheimAbington$627K
Thomas MeyerWynnewood$615K
Surya BhattBethlehem$579K
Tariq CheemaPittsburgh$549K
Stephen KovacsErie$520K
Michael ZlupkoAltoona$468K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →